Identification of MET fusions as novel therapeutic targets sensitive to MET inhibitors in lung cancer

Table 2 Reported lung cancer patients harboring MET fusions and the corresponding treatment information

Reported time [Ref.]	MET fusion types	Primary/ acquired	Stage	EGFR/ALK mutations	Pathological types	The PFS of crizotinib treatment and best overall response
2017 [14]	KIF5B-MET	Primary	IV	WT	LUAD	10.0 months, PR
2017[18]	HLA-DRB1-MET	Primary	IV	WT	LUAD	8.0 months, complete resolution of lung nodules
2018 [18]	KIF5B-MET	Primary	IV	WT	LUAD	8.0 months, PR
2018 [18]	STARD3NL-MET	Primary	IV	WT	LUAD	14.0 months, PR
2018 [18]	MET-ATXN7L1	Primary	IV	WT	LUAD	4 months, PR
2018[18]	MET-UBE2H	Acquired	IV	EGFR exon 19 deletion	LUAD	6.5 months, PR
2019 [15]	CAV1-MET	Acquired	IV	EGFR exon 21 L858R	LUAD, SCLC transformation	NR (plus osimertinib), PR
2020 [19]	HLA-DRB1-MET	Primary	IV	WT	LUAD	7.0 months, complete resolution of lung/brain nodules
2021[18]	HLA-DRB1-MET	Primary	IV	WT	LUAD	NR, CR
2022 [16]	ARL1-MET	Primary	IV	WT	LUAD	5.0 months, PR
2022 [17]	CUX1-MET	Acquired	IV	EGFR exon 18 G719D and exon 21 L861Q	LUAD	9.0 months(plus icotinib), PR
2022 [20]	MET-DSTN	Acquired	IV	EGFR exon 21 L858R	LUAD	NR (plus gefitinib), CR

LUAD lung adenocarcinoma, SCLC small cell lung cancer, WT wild type, NR not reached, PR partial response, CR complete response, ICC intrahepatic cholangiocarcinoma

ISSN: 1479-5876